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Summary  We  describe  two  cases  of  thrombosis  after  mitral  valvuloplasty  (MV).  Antithrom-
botic therapy  after  MV  in  patients  with  no  thromboembolic  risk  factors  is  essentially  based  on
treatment  with  a  platelet  aggregation  inhibitor.  This  strategy  may  not  be  sufﬁcient  in  some
cases and  the  introduction  of  oral  anticoagulant  therapy  may  be  necessary.
© 2011  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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Mitral  valvuloplasty  (MV)  is  currently  the  reference
treatment  for  signiﬁcant  mitral  regurgitation.  The  low
thromboembolic  complication  rate  associated  with  this  pro-
cedure  generally  avoids  the  need  for  anticoagulant  therapy
in  patients  in  sinus  rhythm.  However,  the  optimal  antithrom-
botic  strategy  remains  controversial,  especially  during  the
highest  risk  period,  the  ﬁrst  3  postoperative  months.
We  report  two  rare  cases  of  thrombosis  that  occurred
after  MV  in  Clermont  Ferrand  University  Hospital  and  review
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doi:10.1016/j.jccase.2011.03.006he  guidelines  concerning  antithrombotic  therapy  after  this
rocedure.
ase 1
 69-year-old  man  with  degenerative  mitral  valve  failure
nderwent  MV  in  June  2008,  consisting  of  partial  quadran-
ular  resection  of  P2  with  semi-circumferential  annuloplasty
ver  a  34-mm  Sorin  Sowering® ring.  The  postoperative  result
as  good  with  no  residual  mitral  regurgitation.  Left  ventric-
lar  function  was  almost  normal  (left  ventricular  ejection
raction:  55%).His  postoperative  course  was  uneventful  apart  from  a
ransient  episode  of  complete  atrioventricular  block.  He
ad  sinus  rhythm  at  discharge.  Antithrombotic  therapy  on
ischarge  consisted  of  aspirin  (100  mg/day).
Published by Elsevier Ltd. All rights reserved.
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uFigure  1  (a—d)  Transesophageal  echocardiograp
Two  months  later  he  suffered  a  febrile  episode  during
ehabilitation  and  transesophageal  echocardiography  (TOE)
evealed  a  mobile  4-mm  mass  on  the  lateral  aspect  of  the
itral  ring  (Fig.  1a  and  b).  Due  to  the  absence  of  laboratory
igns  of  inﬂammation,  it  was  decided  to  monitor  the  patient
losely,  with  no  change  of  treatment,  and  to  repeat  TOE  1
onth  later.
Despite  the  absence  of  any  clinical  or  laboratory  signs  of
nfection,  extension  of  the  lesions  was  observed  with  several
obile  images  attached  to  the  ring.  The  two  mitral  leaﬂets
ere  also  very  thickened  and  reorganized  (Fig.  2a  and  b).
The  patient  was  admitted  with  suspected  infective  endo-
arditis  despite  negative  blood  cultures  and  low  C-reactive
rotein.  Intravenous  dual  antibiotherapy  (vancomycin  and
entamicin)  was  started  and  heparin  was  added  4  days  later
ollowing  the  discovery  of  central  venous  catheter  thrombo-
is.
igure  2  Follow-up  by  transesophageal  echocardiography
howing  total  resolution  of  the  thrombotic  episode.
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tD  and  3D)  showing  a  left  atrial  mobile  structure.
TOE  repeated  several  days  later  revealed  total  resolution
f  the  mobile  images  with  persistence  of  minor  mitral  regur-
itation.  A  diagnosis  of  thrombosis  of  the  annuloplasty  ring
as  made  and  vitamin  K  antagonists  (VKA)  were  prescribed.
Three  months  later,  the  patient  was  asymptomatic  and
ransthoracic  echocardiography  (TTE)  conﬁrmed  the  good
esult  of  MV  and  the  absence  of  any  abnormal  valvular
mages.
ase 2
 50-year-old  woman  with  degenerative  mitral  valve  disease
nderwent  MV  in  August  2009,  consisting  of  quadrangular
esection  of  P2  and  semi-circumferential  annuloplasty  on  a
4-mm  Sorin  Sowering® ring.  Her  medical  history  included
hronic  alcoholism  and  active  smoking.
No  postoperative  complication  was  observed.  TTE  on  dis-
harge  showed  normal  left  ventricular  wall  motion  (biplane
jection  fraction:  58%),  moderate  left  atrial  dilation  (28  cm2
n  planimetry),  no  residual  mitral  regurgitation,  and  sinus
hythm.  Antithrombotic  therapy  on  discharge  consisted  of
spirin  (250  mg/day).
In  April  2010,  she  experienced  chest  pain  followed  by  car-
iorespiratory  arrest  and  was  resuscitated  after  ﬁve  shocks
ith  a  semi-automatic  deﬁbrillator.  She  was  urgently  trans-
erred  to  the  coronary  angiography  room  due  to  the  presence
f  ST  elevation  in  the  inferior  leads.  Coronary  angiogra-
hy  demonstrated  a  normal  coronary  network  with  embolic
cclusion  of  retroventricular  branch  of  right  coronary  artery
hich  was  treated  by  thrombo-aspiration  and  balloon  angio-
lasty.  The  thrombo-aspirated  material  consisted  of  a  sterile
brino-thrombotic  thrombus.TOE  showed  good  functioning  of  the  MV  with  no  residual
egurgitation  and  a  small  (7  mm)  mobile  thrombus  situated
n  the  atrial  aspect  of  the  mitral  ring,  adjacent  to  the  pos-
erior  commissure  (Fig.  3a  and  b).
Thrombosis  after  mitral  valvuloplasty  
Figure  3  (a)  Transesophageal  echocardiography  showing  a
left atrial  mobile  structure  and  (b)  coronary  angiography  show-
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iing cup-shaped  occlusion  of  retroventricular  branch  of  right
coronary  artery.
The  diagnosis  was  thrombosis  of  the  mitral  annuloplasty
ring  complicated  by  embolic  inferior  myocardial  infarc-
tion.  Her  subsequent  course  was  favorable  with  localized
wall  motion  abnormality  at  inferior  wall.  Her  thrombophilia
work-up  was  negative  and  the  complication  was  attributed
to  poor  compliance.
Antithrombotic  therapy  on  discharge  consisted  of  aspirin
plus  VKA.
Discussion
MV  is  currently  the  reference  treatment  for  signiﬁcant
mitral  regurgitation  with  excellent  long-term  results  and  a
low  complication  rate,  especially  thromboembolic  compli-
cations  [1].  However,  antithrombotic  therapy  after  MV  has
not  been  clearly  deﬁned.  Although  anticoagulant  therapy  is
indicated  in  patients  with  a  high  embolic  risk  (atrial  ﬁbrilla-
tion,  left  ventricular  dysfunction,  coagulopathy,  left  atrial
dilation),  this  treatment  is  questionable  in  young  patients
at  low  risk.
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Few studies  speciﬁcally  devoted  to  MV  have  been  pub-
ished  and  most  guidelines  for  antithrombotic  therapy  are
ased  on  those  for  aortic  bioprostheses.  Only  the  European
ociety  of  Cardiology  (ESC)  has  proposed  speciﬁc  guidelines
2]:  these  consist  of  3  months  of  postoperative  VKA  in  all
atients  and  then  discontinuation  of  antithrombotic  ther-
py  in  the  absence  of  embolic  risk  factors  (ERF).  These
uidelines  include  the  widespread  use  of  low-dose  aspirin
75—100  mg)  postoperatively  rather  than  anticoagulants  in
atients  with  a  low  embolic  risk,  but  do  not  recommend  this
trategy  due  to  the  absence  of  randomized  trials  conﬁrming
he  safety  of  platelet  aggregation  inhibitors.
The  American  College  of  Chest  Physicians  [3]  recom-
ends  only  low-dose  aspirin  in  aortic  bioprosthesis  patients
ith  no  ERF  (IB).
For  the  American  Heart  Association/American  College
f  Cardiology  and  ESC,  3  months  of  postoperative  VKA  is
ustiﬁed  as  this  period  is  associated  with  the  highest  throm-
oembolic  risk  [4].  This  risk  can  be  explained  by  progressive
ndothelialization  of  the  implant  (prosthesis  or  ring)  and
utures,  inﬂammation,  and  the  high  frequency  of  supraven-
ricular  arrhythmias.
The high  thromboembolic  risk  was  conﬁrmed  in  a  recent
rospective  study  of  1344  patients  undergoing  mitral  valve
urgery  (including  897  mitral  valve  repairs)  [1].  The  lin-
arized  stroke  rate  after  mitral  valve  repair  within  the  ﬁrst
0  days  and  between  30  and  180  days  was  1.5/year  (±0.4%)
nd  2.1/year  (±0.6%),  respectively.  The  relative  risk  of
troke  compared  to  a  similar  population  was  31  and  2.1
t  30  days  and  6  months,  respectively.  Stroke  rates  after  a
ioprosthesis  and  mitral  valve  repair  returns  to  that  of  the
eneral  population  after  180  days  [1].  In  this  study,  treat-
ent  with  VKA  was  only  considered  when  it  was  prescribed
or  more  than  3  months  postoperatively  (41%  of  patients),
ut  no  details  were  provided  concerning  antithrombotic
herapy  received  during  the  ﬁrst  3  months  (heparin  followed
y  VKA  was  generally  used).  Finally,  the  stroke  risk  was
imilar  to  that  in  the  general  population  6  months  after  a
ioprosthesis  or  MV.
Despite  these  guidelines,  there  is  marked  disparity  con-
erning  anticoagulant  management  after  MV.  A  survey
onducted  in  2005  among  British  surgeons  revealed  the  use
f  VKA  in  64%  of  cases  [5].  This  rate  was  only  47%  after
n  aortic  bioprosthesis.  In  France,  many  centers,  including
lermont  Ferrand,  no  longer  use  anticoagulant  therapy  in
hese  indications  in  low-risk  subjects.
In  our  ﬁrst  case,  the  patient  did  not  have  any  ERF
nd,  in  line  with  usual  practice  in  our  hospital,  therefore
nly  received  a  platelet  aggregation  inhibitor  (aspirin).  The
hrombotic  complication  occurred  relatively  early  (begin-
ing  of  the  3rd  postoperative  month)  and  was  discovered
ncidentally.  The  second  patient  had  minor  ERF:  active  smok-
ng  and  moderate  left  atrial  dilation;  and  also  had  poor
ompliance  with  treatment.  The  thromboembolic  compli-
ation  occurred  later,  during  the  8th  postoperative  month.
Such  complications  are  extremely  rare.  To  our  knowl-
dge,  no  case  of  MV  thrombosis  has  been  reported  previously
n  the  literature.  A  literature  review  revealed  two  cases
f  thrombosis  of  mitral  bioprosthesis,  presenting  with
cute  pulmonary  edema  [6,7]. Both  patients  had  a  high
mbolic  risk  (severe  left  ventricular  dysfunction  and  his-
ory  of  stroke,  and  atrial  ﬁbrillation  and  left  atrial  dilation,
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espectively).  The  ﬁrst  patient  received  only  aspirin
325  mg/day)  and  the  thrombosis  occurred  in  the  second
atient  1  month  after  stopping  VKA.
Our  ﬁrst  case  illustrates  the  difﬁcult  differential  diag-
osis  between  thrombus  and  vegetation  and  the  role  of
nticoagulant  therapy  when  clinical  and  laboratory  ﬁndings
re  not  in  favor  of  infective  endocarditis.  In  the  second  case,
acteriological  examination  of  the  thrombus  conﬁrmed  the
bsence  of  infection.
To  conclude,  MV  is  the  current  reference  treatment  for
egenerative  mitral  regurgitation  and  is  associated  with  a
ow  complication  rate,  especially  thromboembolic  events.
owever,  our  two  cases  illustrate  that  thrombotic  compli-
ations  can  occur  after  MV.  Postoperative  antithrombotic
herapy  remains  controversial  and  a  large-scale  randomized
rial  is  required  to  deﬁne  the  optimal  strategy.
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